View Item 

Show simple item record

Article

Opened Access
SEOM clinical guideline for the management of malignant melanoma (2017)

dc.creatorBerrocal, A.es
dc.creatorArance, A.es
dc.creatorCastellón, V. E.es
dc.creatorCruz Merino, Luis de laes
dc.creatorEspinosa, E.es
dc.creatorCao, M. G.es
dc.creatorLarriba, J. L. G.es
dc.creatorMarquez-Rodas, I.es
dc.creatorSoria, A.es
dc.creatorAlgarra, S. M.es
dc.date.accessioned2024-03-12T16:42:20Z
dc.date.available2024-03-12T16:42:20Z
dc.date.issued2018
dc.identifier.citationBerrocal, A., Arance, A., Castellón, V.E., Cruz Merino, L.d.l., Espinosa, E., Cao, M.G.,...,Algarra, S.M. (2018). SEOM clinical guideline for the management of malignant melanoma (2017). Clinical and Translational Oncology, 20 (1), 69-74. https://doi.org/10.1007/s12094-017-1768-1.
dc.identifier.issn1699-048Xes
dc.identifier.issn1699-3055es
dc.identifier.urihttps://hdl.handle.net/11441/156158
dc.description.abstractAll melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic mel anoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical examses
dc.formatapplication/pdfes
dc.format.extent6 p.es
dc.language.isoenges
dc.publisherSpringer Int Publ Ages
dc.relation.ispartofClinical and Translational Oncology, 20 (1), 69-74.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMelanomaes
dc.subjectMetastatices
dc.subjectAdjuvantes
dc.subjectImmunotherapyes
dc.subjectB-RAFes
dc.titleSEOM clinical guideline for the management of malignant melanoma (2017)es
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s12094-017-1768-1es
dc.identifier.doi10.1007/s12094-017-1768-1es
dc.contributor.groupUniversidad de Sevilla. CTS151: Bioquímica médica.es
dc.journaltitleClinical and Translational Oncologyes
dc.publication.volumen20es
dc.publication.issue1es
dc.publication.initialPage69es
dc.publication.endPage74es

FilesSizeFormatViewDescription
SEOM clinical guideline.pdf351.7KbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as: Atribución 4.0 Internacional